Payment overview · 2025
General Payments
$976.11
66 reported records · 19 companies
Healthcare provider profile · identity verified
Shawna E Dellay, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · EVANSVILLE, IN · NPI 1710386214
Verified facts
What the public records show
CMS Open Payments records show Shawna E Dellay, FNP received $976.11 in general payments during 2025 across 66 reported records.
ABBVIE INC. accounted for 28.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Vraylar by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $277.03 | 28.4% | 29 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $202.95 | 20.8% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $80.36 | 8.2% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $76.64 | 7.8% | 4 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $67.36 | 6.9% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.68 | 3.4% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $31.63 | 3.2% | 2 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $24.85 | 2.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $22.07 | 2.3% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.79 | 2.1% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $20.30 | 2.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.05 | 1.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.75 | 1.6% | 1 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $14.79 | 1.5% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $14.68 | 1.5% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.63 | 1.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.32 | 1.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.73 | 1.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.50 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $976.11 | 66 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $202.95 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $183.51 | 22 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $76.64 | 4 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $67.36 | 4 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $67.36 | 4 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $62.39 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $58.63 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $58.63 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $47.38 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $31.13 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $31.13 | 3 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $24.85 | 1 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22.07 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $21.73 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.73 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.73 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $20.79 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $20.79 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.05 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.05 | 1 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $14.79 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $14.68 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $14.63 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.32 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.32 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.73 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.73 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
119 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
32 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 481 | 61 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 454 | 65 |
| Gabapentin | Gabapentin | 363 | 72 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 219 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 196 | 79 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 164 | 51 |
| Atorvastatin Calcium | Atorvastatin Calcium | 156 | 49 |
| Trazodone Hcl | Trazodone Hcl | 147 | 49 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 145 | 51 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 133 | 45 |
| Levothyroxine Sodium | Levothyroxine Sodium | 131 | 40 |
| Prednisone | Prednisone | 125 | 85 |
| Ozempic | Semaglutide | 119 | 27 |
| Furosemide | Furosemide | 117 | 46 |
| Amlodipine Besylate | Amlodipine Besylate | 111 | 42 |
| Ondansetron Hcl | Ondansetron Hcl | 98 | 52 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 94 | 39 |
| Lisinopril | Lisinopril | 94 | 38 |
| Clonazepam | Clonazepam | 92 | 19 |
| Aripiprazole | Aripiprazole | 83 | 35 |
| Oxcarbazepine | Oxcarbazepine | 77 | 23 |
| Omeprazole | Omeprazole | 75 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 71 | 26 |
| Solifenacin Succinate | Solifenacin Succinate | 70 | 28 |
| Diazepam | Diazepam | 68 | 23 |
| Montelukast Sodium | Montelukast Sodium | 64 | 35 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 33 |
| Promethazine Hcl | Promethazine Hcl | 62 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 62 | 24 |
| Buspirone Hcl | Buspirone Hcl | 59 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 59 | 26 |
| Propranolol Hcl Er | Propranolol Hcl | 58 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 57 | 22 |
| Celecoxib | Celecoxib | 54 | 24 |
| Topiramate | Topiramate | 53 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 52 | 14 |
| Losartan Potassium | Losartan Potassium | 52 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 50 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 49 | 17 |
| Pregabalin | Pregabalin | 47 | 11 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 44 | 20 |
| Bupropion Hcl Sr | Bupropion Hcl | 44 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 44 | 13 |
| Modafinil | Modafinil | 43 | suppressed |
| Mounjaro | Tirzepatide | 43 | suppressed |
| Ondansetron Odt | Ondansetron | 43 | 24 |
| Prazosin Hcl | Prazosin Hcl | 41 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 40 | suppressed |
| Baclofen | Baclofen | 39 | suppressed |
| Bupropion Xl | Bupropion Hcl | 39 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | 17 |
| Alprazolam | Alprazolam | 38 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 38 | 11 |
| Famotidine | Famotidine | 38 | 12 |
| Metformin Hcl | Metformin Hcl | 37 | 12 |
| Vraylar | Cariprazine Hcl | 36 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 18 |
| Testosterone Cypionate | Testosterone Cypionate | 35 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 34 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 34 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 33 | 13 |
| Eliquis | Apixaban | 32 | 14 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 32 | 15 |
| Metformin Hcl Er | Metformin Hcl | 30 | 14 |
| Potassium Chloride | Potassium Chloride | 30 | 14 |
| Spironolactone | Spironolactone | 30 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 28 |
| Buprenorphine Hcl | Buprenorphine Hcl | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | 15 |
| Ibuprofen | Ibuprofen | 29 | 14 |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 29 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 28 | 14 |
| Progesterone | Progesterone, Micronized | 27 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 26 | suppressed |
| Oxaprozin | Oxaprozin | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 18 |
| Vyvanse | Lisdexamfetamine Dimesylate | 26 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 24 | suppressed |
| Dutasteride | Dutasteride | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | 23 |
| Oxycontin | Oxycodone Hcl | 24 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 21 |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 22 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 22 | 12 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 21 | 13 |
| Cephalexin | Cephalexin | 20 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 12 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 20 | 19 |
| Estradiol | Estradiol | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 13 |
| Glipizide | Glipizide | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Levemir Flexpen | Insulin Detemir | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Allopurinol | Allopurinol | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 12 |
| Haloperidol | Haloperidol | 13 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $976.11 · 66 records | ABBVIE INC. | ABRYSVO, AREXVY, ARISTADA, Auvelity, Azstarys, BREZTRI, CAPLYTA, COMIRNATY, Dyanavel XR, FANAPT, HETLIOZ, LYBALVI, MAVYRET, MOUNJARO, NURTEC ODT, NUZYRA, OTEZLA, PREVNAR 20, QULIPTA, RELISTOR, REPATHA, REXULTI, SHINGRIX, SUBLOCADE, UBRELVY, VRAYLAR, ZAVZPRET, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error